<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28963273</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>07</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>07</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0029-2559</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>78</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2017</Year>
              <Season>Sep-Oct</Season>
            </PubDate>
          </JournalIssue>
          <Title>North Carolina medical journal</Title>
          <ISOAbbreviation>N C Med J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges.</ArticleTitle>
        <Pagination>
          <StartPage>337</StartPage>
          <EndPage>340</EndPage>
          <MedlinePgn>337-340</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.18043/ncm.78.5.337</ELocationID>
        <Abstract>
          <AbstractText>Rheumatoid arthritis is the most common form of inflammatory arthritis. Because of advances in therapy, clinical outcomes have improved dramatically and remission is possible for many patients. These advances have come with many challenges, prompting consideration of strategies to improve diagnosis and treatment and implement more cost-effective care.</AbstractText>
          <CopyrightInformation>Â©2017 by the North Carolina Institute of Medicine and The Duke Endowment. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pisetsky</LastName>
            <ForeName>David S</ForeName>
            <Initials>DS</Initials>
            <AffiliationInfo>
              <Affiliation>professor of medicine and immunology, Duke University Medical Center; chief, Section of Rheumatology, VA Medical Center, Durham, North Carolina david.pisetsky@duke.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>N C Med J</MedlineTA>
        <NlmUniqueID>2984805R</NlmUniqueID>
        <ISSNLinking>0029-2559</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D059451">Biosimilar Pharmaceuticals</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059451" MajorTopicYN="N">Biosimilar Pharmaceuticals</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28963273</ArticleId>
        <ArticleId IdType="doi">10.18043/ncm.78.5.337</ArticleId>
        <ArticleId IdType="pii">78/5/337</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
